87,974 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by FORA Capital LLC

FORA Capital LLC purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 87,974 shares of the medical research company’s stock, valued at approximately $5,805,000.

Several other institutional investors also recently bought and sold shares of the business. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $29,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences during the second quarter worth $39,000. Finally, Peoples Bank KS acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $40,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock worth $2,657,000 in the last three months. 1.27% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on EW. Wells Fargo & Company decreased their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Performance

EW stock traded up $0.52 during mid-day trading on Wednesday, reaching $72.07. The company had a trading volume of 524,008 shares, compared to its average volume of 4,630,480. The stock’s 50-day simple moving average is $67.83 and its two-hundred day simple moving average is $75.37. The stock has a market capitalization of $42.51 billion, a P/E ratio of 10.33, a P/E/G ratio of 4.01 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.59 EPS. Research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.